A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...